AtriCure, Inc. (NASDAQ:ATRC) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2025 Earnings Conference Call. This call is being recorded for replay purposes.
Atricure Inc. (ATRC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hood River Capital Management David Swank | 3,096,611 | $122,501,931 | +2% | 1.34% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 913,453 | $36,136,202 | +64% | 0.03% |
| 3. | DAFNA Capital Management Nathan Fischel | 597,431 | $23,634,370 | +1% | 5.49% |
| 4. | Defilade Capital Jonathan Forman | 397,636 | $15,730,480 | 2.13% | |
| 5. | Renaissance Technologies Jim Simons | 321,900 | $12,734,364 | +25% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.25 | 5,000 | $111,250.00 | 103,290 | 2024-05-30 | Filing | |
| $76.68 | 34 | $2,607.12 | 16,228 | 2021-04-30 | Filing | |
| $40.54 | 12,350 | $500,669.00 | 41,036 | 2020-11-17 | Filing | |
| $24.86 | 500 | $12,430.00 | 25,670 | 2019-09-12 | Filing | |
| $17.64 | 11,000 | $194,040.00 | 16,805 | 2018-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.83 | 5,000 | $149,150.00 | 96,875 | 2026-03-12 | Filing | |
| $38.00 | 4,967 | $188,746.00 | 34,374 | 2025-11-25 | Filing | |
| $37.32 | 5,033 | $187,831.56 | 34,374 | 2025-11-24 | Filing | |
| $37.29 | 5,166 | $192,640.14 | 78,798 | 2025-11-26 | Filing | |
| $35.72 | 3,000 | $107,160.00 | 11,371 | 2025-11-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,005 | $56,762 | 0% | |
| 2. | 294 | $8,388 | 0% | |
| 3. | 185 | $5,278 | 0% | |
| 4. | 58 | $1,655 | 0% |
News See All
Analysts See an Over 26% Upside in AtriCure (ATRC)
On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
AtriCure, Inc. (NASDAQ:ATRC) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Third Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
Do You Believe in the Upside Potential of Atricure (ATRC)?
Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here.
AtriCure, Inc. (NASDAQ:ATRC) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Second Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure’s First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
AtriCure, Inc. (NASDAQ:ATRC) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Hedge Fund Resource Center